Edwards Lifesciences Corporation
EW · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $44 | $46 | $46 | $81 |
| - Cash | $3 | $1 | $1 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $42 | $46 | $46 | $81 |
| Revenue | $5 | $5 | $5 | $5 |
| % Growth | 8.6% | -6.9% | 2.9% | – |
| Gross Profit | $4 | $4 | $4 | $4 |
| % Margin | 79.5% | 79.3% | 78.3% | 76.6% |
| EBITDA | $2 | $2 | $2 | $2 |
| % Margin | 31.7% | 30.6% | 36.4% | 36.1% |
| Net Income | $4 | $1 | $2 | $2 |
| % Margin | 76.7% | 28% | 28.3% | 28.7% |
| EPS Diluted | 6.97 | 2.3 | 2.44 | 2.38 |
| % Growth | 203% | -5.7% | 2.5% | – |
| Operating Cash Flow | $1 | $1 | $1 | $2 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $1 | $1 | $1 |